trending Market Intelligence /marketintelligence/en/news-insights/trending/vpkjmcpnx16vtujowh9rhw2 content esgSubNav
In This List

Vericel prices $65M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Vericel prices $65M common stock offering

Vericel Corp. priced an underwritten public offering of 5 million common shares at $13 each.

The company expects to raise gross proceeds of $65 million through the offering which is expected to close by June 5. The funds will be used for general corporate purposes, as well as potential acquisitions.

Leerink Partners is acting as lead book runner for the offering, with BTIG LLC also a book runner. Ladenburg Thalmann is acting as co-manager.

The underwriters have a 30-day option to buy up to an additional 750,000 common shares on the same terms and conditions.

Cambridge, Mass.-based Vericel develops patient-specific cellular therapies for severe diseases and conditions.